TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Mangalam Drug & Chem Ltd
MANGALAM

Mangalam Drug & Chem Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 31/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹31.83

Change

+0.18 (0.57%)

Open

₹31.65

Prev. Close

₹31.65

Day High

₹32.48

Day Low

₹31.06

Volume Analysis

Traded

23,815

Delivered

19,744

Delivery %

82.91%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (5)

  • •High debt-to-equity ratio (1.02)
  • •Low return on equity (-35.2%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (31/100)
  • •Low operating margin (-3.9%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹33.94 ₹33.21 ₹32.52 ₹31.79 ₹31.1 ₹30.37 ₹29.68
Fibonacci ₹33.21 ₹32.67 ₹32.33 ₹31.79 ₹31.25 ₹30.91 ₹30.37
Camarilla ₹32.22 ₹32.09 ₹31.96 ₹31.79 ₹31.7 ₹31.57 ₹31.44

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+10.21%

1 Week

-2.54%

1 Month

-0.34%

3 Months

+13.11%

6 Months

+11.68%

1 Year

-55.93%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-37.09%

Net margin -16.38% × asset turnover 0.74x × equity multiplier 3.06x

Company Overview

Sector

Healthcare

Market Cap

₹50 Cr

ROE

-35.2%

Book Value

₹65.1

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.

TopFund Analysis

Mangalam Drug & Chem Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 31/100. The strongest factor is Risk & Volatility (64/100), while Cash Flow (3/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.02); low return on equity (-35.2%).

TopFund Score — Fundamentals Quality

31/100 — Weak

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

58

Valuation

24

Cash Flow

3

Corporate Governance

36

Momentum

16

Institutional Ownership

30

Business Quality

14

Risk & Volatility

64

Liquidity

50

From Screener.in

  • +Stock is trading at 0.49 times its book value
  • −Company has low interest coverage ratio.
  • −Promoter holding is low: 35.6%
  • −Company has a low return on equity of -11.6% over last 3 years.
  • −Contingent liabilities of Rs.34.6 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Closure of Trading Window 25 Sep

Trading window closed from October 1, 2026 until 48 hours after Q2 FY27 results.

Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 24 Sep

Shareholders approved appointing new secretarial and statutory auditors for five years at 53rd AGM.

Announcement under Regulation 30 (LODR)-Retirement 24 Sep

53rd AGM appointed L.N. Joshi & Co. as secretarial auditor and S.N. Nanda & Co. as statutory auditor for five years.

Announcement under Regulation 30 (LODR)-Change in Management 24 Sep

53rd AGM appointed L.N. Joshi & Co. as secretarial auditor and S.N. Nanda & Co. as statutory auditor for five years.

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 24 Sep 24 Sep

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 97 102 77 80 89 73 57 50 58 67 57
Expenses + 90 91 68 71 80 63 62 52 60 73 56
Operating Profit 7 12 8 9 9 10 -5 -3 -2 -6 1
OPM % 7.17% 11.43% 10.7% 10.88% 9.89% 13.6% -8.08% -5.73% -2.64% -8.35% 1.59%
Other Income + 0 0 0 0 0 0 0 0 0 0 0
Interest 3 4 4 4 3 4 4 5 4 3 4
Depreciation 4 4 4 4 4 5 4 5 4 5 4
Profit before tax 0 4 1 1 1 2 -13 -12 -10 -13 -7
Tax % -1,150.0% 10.18% -362.07% -124.17% 5.84% 95.73% 6.15% -41.06% 0.0% 1.13% 13.19%
Net Profit + 1 4 3 3 1 0 -14 -7 -10 -13 -8
EPS in Rs 0 2 2 2 1 0 -9 -5 -6 -8 -5
Raw PDF — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 369 318 232 232
Expenses + 351 282 247 241
Operating Profit 17 36 -15 -9
OPM % 4.7% 11.0% -6.0% -3.9%
Other Income + 0 0 1 0
Interest 14 15 16 16
Depreciation 15 17 18 18
Profit before tax -11 5 -49 -42
Tax % -18.0% -41.0% -9.0% —
Net Profit + -9 7 -44 -38
EPS in Rs -6 4 -28 -24
Dividend Payout % 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2024 Mar 2025 Mar 2026
Reserves 120 133 87
Borrowings + 107 96 105
Other Liabilities + 91 121 106
Total Liabilities 334 366 315
Fixed Assets + 148 163 159
CWIP 8 3 0
Investments 0 0 0
Other Assets + 178 201 156
Total Assets 334 366 315
Equity Capital 16 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 4 43 4
Cash from Investing Activity + -12 -19 -12
Cash from Financing Activity + 5 -22 6
Net Cash Flow -3 1 -2
CFO/OP 23 118 -30
Free Cash Flow -8 23 -8

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.31% → 35.65%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 49.59% 49.59% 49.42% 49.47% 49.58% 49.58% 49.23% 49.16% 49.57% 64.22% 64.03% 64.24%
Promoters 50.31% 50.31% 50.31% 50.31% 50.3% 50.3% 50.3% 50.3% 50.3% 35.64% 35.65% 35.65%
FII 0.1% 0.1% 0.26% 0.21% 0.11% 0.11% 0.47% 0.53% 0.11% 0.13% 0.32% 0.11%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Mangalam Drug & Chem Ltd (this stock) 50 — 0.49 -35.2%
Vivimed Labs Limited 46 — -0.22 —
Vivo Bio Tech Ltd. 38 — 0.4 -2.0%
Gkb Ophthalmics Ltd. 36 9.69 0.66 3.28%
Medi Caps Ltd. 31 — 0.28 -9.21%
Sunil Healthcare Ltd. 78 21.1 1.12 6.01%
Ortin Global Limited 12 — — —

Which Mutual Funds Hold Mangalam Drug & Chem Ltd?

Frequently Asked Questions about Mangalam Drug & Chem Ltd

Community Sentiment

What are other investors saying about Mangalam Drug & Chem Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.